

	High	Low	Median
<b>Prospective (Blood measures)</b>			
Laden, 2001 (372/372)	1.37	0.49	0.82
Høyer, 2000 (155/274)	2.8	0.7	1.4
Ward, 2000 (150/150)			1.2
Wolff, 2000a (148/295)	3.35	0.51	1.3
Helzlouer, 1999 (1989: 346/346)	1.17	0.29	0.58
Helzlouer, 1999 (1974: 346/346)	1.32	0.4	0.73
Dorgan, 1999 (105/207)	1.5	0.4	0.8
Hoyer, 1998 (237/469)	1.37	0.56	0.88
Hunter, 1997 (236/236)	1.4	0.37	0.72
Krieger, 1994 (150/150)	2.2	0.68	1.33
Wolff, 1993 (58/171)	13.5	1.01	3.68
<b>Retrospective Case Control (Blood Measures)</b>			
Pavuk, 2003 (24/88)	14.3	0.65	3.04
Millikan, 2000 (748/659)	1.51	0.79	1.09
Millikan, 2000 (African American)	2.29	0.87	1.41
Millikan, 2000 (White)	1.43	0.68	0.98
Gammon, 2002 (646/428)	1.9	0.76	1.2
Demers, 2000 (315/219 hospital controls)	2.63	0.71	1.36
Demers, 2000 (315/307 population controls)	1.67	0.6	1
Romieu, 2000 (Stratified, 120/126)	5.5	0.85	2.16
Romieu, 2000 (Not-stratified, 120/126)	2.32	1.09	1.59
Wolff, 2000b (175/355)	1.5	0.56	0.93
Zheng, 2000 (475/502)	1.36	0.67	0.96
Dello Iacovo, 1999 (170/195)	2.2	0.7	1.24
Mendonca, 1999 (177/350)	1.73	0.47	0.9
Moysich, 1998 (154/192)	2.55	0.71	1.34
Olaya-Contreras, 1998 (153/153)	3.52	1.1	1.95
Schrecker, 1997 (21/21)	5.98	0.23	1.14
Lopez-Carillo, 1997 (141/141)	1.42	0.41	0.76
<b>Retrospective Case Control (Adipose Measures)</b>			
Bagga, 2000 (73/73)	1.603	0.792	1.126
Aronson, 2000 (217/213)	3.11	0.84	1.62
Stellman, 2000 (232/323)	1.25	0.44	0.74
Zheng, 1999 (304/186)	1.5	0.5	0.9
Liljegren, 1998 (35/43)	1.2	0.1	0.4
V'ant Veer, 1997 (347/347)	0.95	0.25	0.48
<b>Hormone Receptor Status (Blood measures)</b>			
Gammon, 2002 (208 ER+ PR+/417)	1.7	0.69	1.1
Gammon, 2002 (45 ER+ PR-/417)	2.45	0.2	0.7
Gammon, 2002 (21 ER- PR+/417)	4.37	0.25	1.24
Gammon, 2002 (80 ER- PR-/417)	1.86	0.48	0.95
Høyer, 2001 (116 ER+/226)	1.5	0.6	0.9
Høyer, 2001 (44 ER-/92)	0.2	1.7	0.6

**Hormone Receptor Status  
(Adipose measures)**


Woolcott, 2001 (51 ER-/208)	5.4	1	2.4
Woolcott, 2001 (147 ER+/208)	1.9	0.6	1.1

**Other Studies**

Høyer, 2002 (36 p53 mut/72)	2.84	0.23	0.81
Høyer, 2002 (123 wildtype p53/244)	1.83	0.5	0.96

# Plot of odds/risk ratios of the association between breast cancer and DDE

Ratios expressed as upper compared to lower stratification. Only studies reporting odds/risk ratios shown




Care must be taken when viewing this graph as the relative risks/odds ratios are those reported in individual studies. The data have not been recalculated in terms of unit exposures.

	High	Low	Median	
<b>Prospective (Blood measures)</b>				
<b>(Cases/Controls)</b>				
Hoyer, 2000b (155/274)	12.2	1.1	3.6	
Ward, 2000 (150/150)			0.3	nd
Dorgan, 1999 (p,p' DDT: 105/207)	1	0.2	0.4	
Dorgan, 1999 (Total DDT: 105/207)	1.6	0.4	0.8	
Hoyer, 1998 (p,p' DDT: 237/469)	1.87	0.76	1.19	
Hoyer, 1998 (Total DDT: 237/469)	1.45	0.49	0.84	
<b>Retrospective Case Control (Blood Measures)</b>				
<b>(Cases/Controls)</b>				
Pavuk, 2003 (24/88)	5.23	0.27	1.19	
Charlier, 2003 (Total DDR: 159/250)	17.65	1.81	5.64	
Gammon, 2002 (646/428)	1.79	0.74	1.15	>0.05
Demers, 2000 Risk Ratio (315/219 hospital controls)	2.56	0.73	1.37	nd
Demers, 2000 (315/307 population controls)	1.37	0.48	0.81	nd
Romieu, 2000 not-stratified (120/126)	1.43	0.74	1.03	nd
Wolff, 2000b (175/355)	2.2	0.82	1.34	0.241
Schrechter, 1997 (21/21)	5.68	0.23	1.21	nd
<b>Retrospective Case Control (Adipose Measures)</b>				
<b>(Cases/Controls)</b>				
Bagga, 2000 (73/73)	0.191	0.93	1.052	
Aronson, 2000 (217/213)	2.29	0.61	1.18	nd
Zheng, 1999 (304/186)	1.5	0.5	0.8	
<b>Other Studies</b>				
<b>(Cases/Controls)</b>				
Høyer, 2002 (p,p' DDT: 36 p53/72)	2.98	0.3	0.95	0.98
Høyer, 2002 (p,p' DDT: 123 wildtype/244)	2.59	0.68	1.32	0.85
Høyer, 2002 (Total DDT: 36 p53/72)	4.17	0.19	0.88	0.98
Høyer, 2002 (Total DDT: 123 wildtype/244)	1.55	0.32	0.7	0.85

## Plot of odds/risk ratios of the association between breast cancer and DDT

Ratios expressed as upper compared to lower stratification. Only studies reporting odds/risk ratios shown



Care must be taken when viewing this graph as the relative risks/odds ratios are those reported in individual studies. The data have not been recalculated in terms of unit exposures.

High Low Median

**Prospective (Blood measures)  
(Cases/Controls)**

Hoyer, 2000b (155/274)	3	0.5	1.2
Ward, 2000 (150/150)			0.7
Dorgan, 2000 (150/150)	1.5	0.3	0.7
Hoyer, 1998 (237/469)	2.33	0.79	1.36

**Retrospective Case Control (Blood  
Measures)  
(Cases/Controls)**

Lopez-Carillo, 2002 (95/95)	2.4	0.46	1.05	0.8
Demers, 2000 (315/219 hospital controls)	1.61	0.43	0.83	nd
Demers, 2000 (315/307 population controls)	1.35	0.47	0.8	nd

**Retrospective Case Control  
(Adipose Measures)  
(Cases/Controls)**


Aronson, 2000 (217/213)	1.4	0.34	0.69	nd
-------------------------	-----	------	------	----

**Hormone Receptor Status (Adipose  
measures)  
(Cases/Controls)**

Woolcott, 2001 (51 ER-/208)	3.2	0.6	1.4	nd
Woolcott, 2001 (147 ER+/208)	1.3	0.4	0.7	nd

## Plot of odds/risk ratios of the association between breast cancer and $\beta$ -HCH

Ratios expressed as upper compared to lower stratification. Only studies reporting odds/risk ratios shown




Care must be taken when viewing this graph as the relative risks/odds ratios are those reported in individual studies. The data have not been recalculated in terms of unit exposures.

	High	Low	Median	
<b>Prospective (Blood measures)</b>				
<b>(Cases/Controls)</b>				
Dorgan, 1999 (105/207)	1.4	0.3	0.6	
Hoyer, 1998 (237/469)	3.57	1.17	2.05	
<b>Retrospective Case Control (Blood Measures)</b>				
<b>(Cases/Controls)</b>				
Gammon, 2002 (646/428)	2.72	0.69	1.37	
<b>Hormone Receptor Status (Blood measures)</b>				
<b>(Cases/Controls)</b>				
Høyer, 2001 (116 ER+/226)	2.5	0.8	1.4	>0.2
Høyer, 2001 (44 ER-/92)	46.1	1.3	7.6	0.01
<b>Other Studies</b>				
<b>(Cases/Controls)</b>				
Høyer, 2002 (36 p53 mut/72)	15.79	0.79	3.53	nd
Høyer, 2002 (123 wildtype p53/244)	2.58	0.56	1.2	nd

## Plot of odds/risk ratios of the association between breast cancer and Dieldrin

Ratios expressed as upper compared to lower stratification. Only studies reporting odds/risk ratios shown



Care must be taken when viewing this graph as the relative risks/odds ratios are those reported in individual studies. The data have not been recalculated in terms of unit exposures.